Epitalon is sold as a longevity peptide first and a sleep aid second. The sleep pitch runs through melatonin: epitalon is said to "restore" the pineal gland's night-time melatonin output, and better sleep is said to follow. This page checks each link in that chain against the published record, with the searches printed so they can be repeated.
The dose figures, the extract-versus-peptide distinction and the July 2026 advisory vote are on our epitalon dosage page; what FDA's 2026 review found on safety is on epitalon side effects. Peptide Lexicon's sleep peptides overview sets epitalon beside the other compounds sold for sleep. Nothing here is a recommendation; a sleep problem that persists is a question for a physician.
Step one: has anyone measured sleep?
Search run on PubMed, 2 November 2026:
(epitalon[tiab] OR epithalon[tiab] OR epithalone[tiab] OR epithalamin[tiab]) AND sleep[tiab]
It returns two records. One is a 2026 orthopaedics review that lists epithalon among "recovery-enhancing agents" targeting "circadian and mitochondrial regulators", citing no sleep study. The other is a 2004 review of mouse lifespan experiments in which the word appears only in the name of a different compound, delta sleep-inducing peptide.
So no study in people or animals has given epitalon or epithalamin and measured sleep — not total sleep time, not time to fall asleep, not sleep stages on a polysomnogram. That is the most important fact on this page, and it is checkable in under a minute.
For contrast, the compound actually named after sleep, DSIP, has fourteen human sleep studies, and they split along authorship lines; that record is on DSIP for sleep.
Step two: what the melatonin papers show
Widening the search to melatonin and circadian rhythm, limited to human records, returns 17 records, most of them reviews. Four report a measurement in people after a course of a pineal peptide product:
| Paper | Product given | Who | What was measured | Reported |
|---|---|---|---|---|
| Korkushko et al., Bull Exp Biol Med 2004 | Epithalamin (pineal extract) | Healthy elderly people | Plasma melatonin across 24 hours | Night melatonin rose where it started low; tended to fall where it was normal |
| Korkushko et al., Adv Gerontol 2007 | Epithalamin and epitalon | Elderly people; old rhesus monkeys | Plasma melatonin rhythm | Night melatonin rose in people with "pineal insufficiency" |
| Trofimova et al., Adv Gerontol 2017 | Pineamin, another pineal complex | 55 elderly patients | Night urinary 6-sulfatoxymelatonin | 1.9 times the pre-treatment level |
| Ivko et al., Adv Gerontol 2020 | AEDG peptide (Ala-Glu-Asp-Gly, the epitalon sequence) | Middle-aged people with low starting values | Urinary 6-sulfatoxymelatonin; clock-gene expression in white cells | 6-sulfatoxymelatonin 1.7 times higher; Clock, Csnk1e and Cry2 expression moved toward normal |
Sources: the PubMed abstracts listed below, read 2 November 2026. 6-sulfatoxymelatonin is melatonin's main breakdown product in urine, a standard proxy for night-time melatonin output.
Four things limit what the table can carry:
- Only one of the four used the synthetic tetrapeptide alone (Ivko 2020). Two used the extract, one a different product, one both. A result for a calf pineal extract is not a result for a vial of epitalon.
- None measured sleep. A higher melatonin level is not, by itself, better sleep; the step from one to the other is assumed, not tested.
- None of the abstracts reports a placebo group, and only the 2017 paper gives a participant count (55) or a course dose (100 mg of Pineamin). The 2004 paper carries a randomised-trial publication tag, but its abstract describes a before-and-after comparison.
- All four involve the St Petersburg Institute of Bioregulation and Gerontology, which developed the compound, or its founder V. Kh. Khavinson as an author.
FDA's 2026 briefing for its compounding advisory committee, as read on our epitalon side-effects page, counts the human studies of synthetic epitalon the same way: two gave it under the tongue to night-shift workers and looked at clock genes and a melatonin metabolite, and a third was an eye-disease study. None measured sleep.
The most recent independent appraisal reaches the same place. A narrative review by anaesthesiology and rehabilitation physicians at Johns Hopkins, Harvard and other US centres, published on 8 October 2026 in the International Journal of Molecular Sciences, describes the human evidence as "limited to small physiological or biomarker studies" and concludes that epitalon is "biologically active but clinically unproven".
The animal work behind the claim comes from the same source: two 2001 papers report that epitalon stimulated evening melatonin and normalised cortisol rhythms in old female rhesus monkeys (Goncharova, Khavinson and Lapin; Khavinson, Goncharova and Lapin).
Step three: the test that found nothing
One experiment tested the tetrapeptide's effect on melatonin in a laboratory outside St Petersburg. In 2003 Djeridane and Touitou's group at the Pitié-Salpêtrière faculty in Paris, with Khavinson and Anisimov as co-authors, perfused pineal glands from young (9-week) and old (27-month) rats with Ala-Glu-Asp-Gly at three concentrations.
The result, in the paper's words: the tetrapeptide "had no significant effect upon melatonin secretion whatever the age of the animals", and it did not change the melatonin rise produced by the stimulant isoproterenol. The authors concluded it "does not seem to play a role, at least in vitro, in the control of melatonin secretion by the rat pineal gland."
That is an isolated-gland experiment, not a living animal, and it cannot rule out an effect that works through the rest of the body. It is still the one measurement of the claimed mechanism made away from the originating institute, and it came back null. Retail pages that cite the melatonin claim do not mention it.
The two-way effect
The human melatonin papers describe the effect as "normalising": melatonin goes up in people whose levels started low and tends to go down in people whose levels were normal. The 1983 hormone work on the extract, described on the dosage page, reports the same two-way pattern for gonadotropins and prolactin. A result that moves toward normal from either direction is hard to test, because regression to the mean — extreme starting values drifting back toward average on remeasurement — produces the same picture without any drug. A placebo group would separate the two; none of the abstracts reports one.
What is not established
- Any effect of epitalon on sleep, measured in any species.
- A melatonin effect of synthetic epitalon in a placebo-controlled human study.
- Replication of the melatonin effect by an independent group; the one outside test, in rat pineal glands, found none.
- A registered trial. ClinicalTrials.gov returns one study naming epitalon (searched 2 November 2026): NCT07888595, an ageing-clock study of a topical peptide serum enrolling from October 2026, with no sleep outcome.
- The route. The night-shift studies FDA describes gave epitalon under the tongue; research-market epitalon is sold for subcutaneous injection, and no study counted here measured melatonin or sleep after an injection under the skin.
Sources
- Korkushko OV, Khavinson VKh, Shatilo VB, Magdich LV. Bull Exp Biol Med 2004;137(4):389–91. PMID 15452611.
- Korkushko OV, Lapin BA, Goncharova ND, Khavinson VKh et al. Adv Gerontol 2007;20(1):74–85. PMID 17969590.
- Trofimova SV et al. [Pineamin increased pineal melatonin synthesis in elderly people]. Adv Gerontol 2017. PMID 28849889.
- Ivko OM, Linkova NS, Ilina AR, Sharova AA, Ryzhak GA. Adv Gerontol 2020;33(3):429–35. PMID 33280326.
- Djeridane Y, Khavinson VKh, Anisimov VN, Touitou Y. J Endocrinol Invest 2003;26(3):211–5. PMID 12809170.
- Goncharova ND, Khavinson VKh, Lapin BA. Bull Exp Biol Med 2001;131(4):394–6. PMID 11550036.
- Khavinson V, Goncharova N, Lapin B. Neuro Endocrinol Lett 2001;22(4):251–4. PMID 11524632.
- Jain A, Gallacher DM, Issa MA et al. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. Int J Mol Sci 2026;27(19):8922. PMID 42884164.
- Reviews returned by the sleep search: J Am Acad Orthop Surg Glob Res Rev 2026;10(1), PMID 41490200; Adv Gerontol 2004;14:105–13, PMID 15559508.
- PubMed E-utilities and ClinicalTrials.gov API v2 searches as printed above, run 2 November 2026.